Clinical Trial

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-108 in relapsed/refractory autoimmune diseases.
Trial Details
NCT Number NCT06980597
Lead Sponsor Beijing GoBroad Hospital
Conditions Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV)
Enrollment 44 participants
Start Date 2025-06
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-20